ADARx Pharmaceuticals, Inc. Common Stock (ADRX)

• Market cap: $1.95B
• 1 day: -6.6%
• 5 days: -3.95%
• 1 month: -5.68%
• 3 months: -5.68%
• 6 months: -5.68%
• Year to date: -5.68%
• 1 year: -5.68%
• 5 years: -5.68%
• 10 years: -5.68%
• Sector: Healthcare
• Industry: Biotechnology

About: Adarx Pharmaceuticals Inc is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. Its pipeline includes three clinical-stage programs and two advanced preclinical programs. The three hepatic-targeted programs are agazisiran, onvuzosiran, and ADX-626, while the two extrahepatic-targeted programs are ADX-077 and ADX-199.